Efficacy results for EPKINLY (N=148)1,2
61% of patients had a response and 38% of patients had a CR
Efficacy results were determined by Lugano criteria (2014) as assessed by Independent Review Committee (IRC).
Duration of response1,2
*Based on Kaplan-Meier estimate.
ORR and CR rates observed in select prespecified subgroups2
CAR T=chimeric antigen receptor T cell; CI=confidence interval; CR=complete response; DOR=duration of response; NHL=non-Hodgkin lymphoma; ORR=overall response rate; PR=partial response.